Pharmacologic treatment of neonatal hyperbilirubinemia.
D000293:Adolescent; D000818:Animals; D001224:Aspartic Acid / Q000627:therapeutic use; D001663:Bilirubin / Q000378:metabolism; D003634:DDT / Q000627:therapeutic use; D003975:Diazepam / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D000431:Ethanol / Q000627:therapeutic use; D005260:Female; D003932:Heroin / Q000494:pharmacology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007408:Intestinal Absorption; D007567:Jaundice, Neonatal / Q000188:drug therapy*; D008099:Liver / Q000378:metabolism; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D009552:Nikethamide / Q000627:therapeutic use; D009963:Orotic Acid / Q000627:therapeutic use; D010634:Phenobarbital / Q000494:pharmacology* / Q000627:therapeutic use; D010789:Phototherapy; D012709:Serum Albumin / Q000378:metabolism; D013268:Stimulation, Chemical
D012709:Serum Albumin; D001224:Aspartic Acid; D009552:Nikethamide; D000431:Ethanol; D009963:Orotic Acid; D003932:Heroin; D003634:DDT; D003975:Diazepam; D001663:Bilirubin; D010634:Phenobarbital